{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:45:04Z","timestamp":1790844304963,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most current antimalarial drugs are combinations of an artemisinin plus a \u2018partner\u2019 drug from another class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs in treating human malaria infections. They also have a public-health role as an essential component of recent, comprehensive scale-ups of malaria interventions and containment efforts conceived as part of longer term malaria elimination efforts. Recent reports that resistance has arisen to artemisinins has caused considerable concern. We investigate the likely impact of artemisinin resistance by quantifying the contribution artemisinins make to the overall therapeutic capacity of ACTs. We achieve this using a simple, easily understood, algebraic approach and by more sophisticated pharmacokinetic\/pharmacodynamic analyses of drug action; the two approaches gave consistent results. Surprisingly, the artemisinin component typically makes a negligible contribution (\u226a0.0001%) to the therapeutic capacity of the most widely used ACTs and only starts to make a significant contribution to therapeutic outcome once resistance has started to evolve to the partner drugs. The main threat to antimalarial drug effectiveness and control comes from resistance evolving to the partner drugs. We therefore argue that public health policies be re-focussed to maximise the likely long-term effectiveness of the partner drugs.<\/jats:p>","DOI":"10.1038\/srep32762","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T09:07:04Z","timestamp":1473325624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Quantifying the pharmacology of antimalarial drug combination therapy"],"prefix":"10.1038","volume":"6","author":[{"given":"Ian M.","family":"Hastings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Hodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"key":"BFsrep32762_CR1","unstructured":"World Health Organization. World Malaria Report 2015. URL:http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2015\/report\/en\/ (2016)."},{"key":"BFsrep32762_CR2","unstructured":"World Health Organization. Emergency response to artemisinin resistance in the greater Mekong subregion. Regional Framework for action 2013\u20132015. (World Health Organization, 2013)."},{"key":"BFsrep32762_CR3","doi-asserted-by":"publisher","first-page":"EI10","DOI":"10.1128\/microbiolspec.EI10-0013-2016","volume":"4","author":"RM Fairhurst","year":"2016","unstructured":"Fairhurst, R. M. & Dondorp, A. M. Artemisinin-Resistant Plasmodium falciparum Malaria. Microbiol. Spectr. 4, EI10\u20130013. doi: 10.1128\/microbiolspec.EI10-0013-2016 (2016).","journal-title":"Microbiol. Spectr"},{"key":"BFsrep32762_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMe1407026","volume":"371","author":"B Greenwood","year":"2014","unstructured":"Greenwood, B. Treatment of malaria - A continuing challenge. N. Eng. J. Med. 371, 474\u2013475 (2014).","journal-title":"N. Eng. J. Med."},{"key":"BFsrep32762_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4269\/ajtmh.2012.12-0025","volume":"87","author":"RM Fairhurst","year":"2012","unstructured":"Fairhurst, R. M. et al. Artemisinin-resistant malaria: Research challenges, opportunities, and public health implications. Am. J. Trop. Med. Hyg. 87, 231\u2013241 (2012).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFsrep32762_CR6","doi-asserted-by":"crossref","unstructured":"International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363, 9-17 (2004).","DOI":"10.1016\/S0140-6736(03)15162-8"},{"key":"BFsrep32762_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pt.2010.09.005","volume":"27","author":"IM Hastings","year":"2011","unstructured":"Hastings, I. M. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends in Parasitol. 27, 67\u201372 (2011).","journal-title":"Trends in Parasitol"},{"key":"BFsrep32762_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pt.2005.12.011","volume":"22","author":"IM Hastings","year":"2006","unstructured":"Hastings, I. M. & Watkins, W. M. Tolerance is the key to understanding antimalarial drug resistance. Trends in Parasitol. 22, 71\u201377 (2006).","journal-title":"Trends in Parasitol"},{"key":"BFsrep32762_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1098\/rstb.2001.1036","volume":"357","author":"IM Hastings","year":"2002","unstructured":"Hastings, I. M., Watkins, W. M. & White, N. J. The evolution of drug resistant malaria; the role of drug elimination half-life. Phil. Trans. R. Soc. Lond. [B] 357, 505\u2013519 (2002).","journal-title":"Phil. Trans. R. Soc. Lond. [B]"},{"key":"BFsrep32762_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0810-4","volume":"14","author":"K Kay","year":"2015","unstructured":"Kay, K. & Hastings, I. M. Measuring windows of selection for anti-malarial drug treatments. Malaria Journal 14, 1\u201310, doi: 10.1186\/s12936-015-0810-4 (2015).","journal-title":"Malaria Journal"},{"key":"BFsrep32762_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","volume":"371","author":"DL Saunders","year":"2014","unstructured":"Saunders, D. L., Vanachayangkul, P. & Lon, C. Dihydroartemisinin\u2013Piperaquine Failure in Cambodia. N. Eng J. Med. 371, 484\u2013485, doi: 10.1056\/NEJMc1403007 (2014).","journal-title":"N. Eng J. Med."},{"key":"BFsrep32762_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga, C. et al. Dihydroartemisin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect. Dis. 16, 357\u2013365, doi: 10.1016\/S1473-3099(15)00487-9 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep32762_CR13","doi-asserted-by":"crossref","unstructured":"Phyo, A. P. et al. Declining Efficacy of Artemisinin Combination Therapy Against P. falciparum Malaria on the Thai\u2013Myanmar Border (2003\u20132013): The Role of Parasite Genetic Factors. Clin. Infect. Dis. doi: 10.1093\/cid\/ciw388 (2016).","DOI":"10.1093\/cid\/ciw388"},{"key":"BFsrep32762_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature15535","volume":"526","author":"S Bhatt","year":"2015","unstructured":"Bhatt, S. et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526, 207\u2013211, doi: 10.1038\/nature15535 (2015).","journal-title":"Nature"},{"key":"BFsrep32762_CR15","doi-asserted-by":"crossref","unstructured":"Johnston, G. L., Gething, P. W., Hay, S. I., Smith, D. L. & Fidock, D. A. Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination. PLoS Comput Biol 10, doi: 10.1371\/journal.pcbi.1003434 (2014).","DOI":"10.1371\/journal.pcbi.1003434"},{"key":"BFsrep32762_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo, A. P. et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: A longitudinal study. Lancet 379, 1960\u20131966 (2012).","journal-title":"Lancet"},{"key":"BFsrep32762_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N. Engl. J. Med. 371, 411\u2013423, doi: 10.1056\/NEJMoa1314981 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep32762_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1128\/AAC.00903-07","volume":"52","author":"K Stepniewska","year":"2008","unstructured":"Stepniewska, K. & White, N. J. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52, 1589\u20131596 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32762_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1086\/427997","volume":"191","author":"C Sisowath","year":"2005","unstructured":"Sisowath, C. et al. In vivo selection of Plasmodium falciparum pfmdr 1 86N coding alleles by Artemether-Lumefantrine (Coartem). J. Infect. Dis. 191, 1014\u20131017 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFsrep32762_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1086\/432554","volume":"192","author":"IM Hastings","year":"2005","unstructured":"Hastings, I. M. & Ward, S. A. Coartem in Africa- the beginning of the end? J. Infect. Dis. 192, 1303\u20131304 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFsrep32762_CR21","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1128\/aac.00482-15","volume":"59","author":"K Kay","year":"2015","unstructured":"Kay, K., Hodel, E. M. & Hastings, I. M. Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness. Antimicrob. Agents Chemother. 59, 6419\u20136427, doi: 10.1128\/aac.00482-15 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32762_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/infdis\/jiu427","volume":"211","author":"PA Ndour","year":"2015","unstructured":"Ndour, P. A. et al. Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria. J Infect Dis 211, 290\u2013297, doi: 10.1093\/infdis\/jiu427 (2015).","journal-title":"J Infect Dis"},{"key":"BFsrep32762_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/infdis\/jit082","volume":"207","author":"TM Lopera-Mesa","year":"2013","unstructured":"Lopera-Mesa, T. M. et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: Effect of acquired immunity. J. Infect. Dis. 207, 1655\u20131663 (2013).","journal-title":"J. Infect. Dis."},{"key":"BFsrep32762_CR24","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1128\/aac.00481-15","volume":"59","author":"IM Hastings","year":"2015","unstructured":"Hastings, I. M., Kay, K. & Hodel, E. M. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob. Agents Chemother. 59, 6428\u20136436, doi: 10.1128\/aac.00481-15 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32762_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pt.2013.05.002","volume":"29","author":"PE Ferreira","year":"2013","unstructured":"Ferreira, P. E., Culleton, R., Gil, J. P. & Meshnick, S. R. Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol 29, 318\u2013320, 10.1016\/j.pt.2013.05.002 (2013).","journal-title":"Trends Parasitol"},{"key":"BFsrep32762_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4269\/ajtmh.2012.12-0388","volume":"87","author":"S Meshnick","year":"2012","unstructured":"Meshnick, S. Perspective: Artemisinin-resistant malaria and the wolf. Am. J. Trop. Med Hyg. 87, 783\u2013784 (2012).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"BFsrep32762_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.pt.2013.04.001","volume":"29","author":"S Krishna","year":"2013","unstructured":"Krishna, S. & Kremsner, P. G. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 29, 313\u2013317 (2013).","journal-title":"Trends Parasitol"},{"key":"BFsrep32762_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/infdis\/jiq001","volume":"203","author":"J Ursing","year":"2011","unstructured":"Ursing, J. et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J. Infect. Dis. 203, 109 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFsrep32762_CR29","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1128\/aac.00287-13","volume":"57","author":"NJ White","year":"2013","unstructured":"White, N. J. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob. Agents Chemother. 57, 5792\u20135807, doi: 10.1128\/aac.00287-13 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32762_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring, M. D. et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect. Dis. 15, 683\u2013691, doi: 10.1016\/S1473-3099(15)70049-6 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep32762_CR31","doi-asserted-by":"crossref","unstructured":"Shanks, G. D., Edstein, M. D. & Jacobus, D. Evolution from double to triple-antimalarial drug combinations. Trans. R. Soc. Trop. Med. Hyg., doi: 10.1093\/trstmh\/tru199 (2014).","DOI":"10.1093\/trstmh\/tru199"},{"key":"BFsrep32762_CR32","unstructured":"A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC) (TRACII), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453308 (2015)."},{"key":"BFsrep32762_CR33","doi-asserted-by":"crossref","unstructured":"malERA. A Research Agenda for Malaria Eradication: Modeling. PLoS Med 8, e1000403, doi: 10.1371\/journal.pmed.1000403 (2011).","DOI":"10.1371\/journal.pmed.1000403"},{"key":"BFsrep32762_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-1075-7","volume":"15","author":"HC Slater","year":"2016","unstructured":"Slater, H. C., Griffin, J. T., Ghani, A. C. & Okell, L. C. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malaria J. 15, 1\u201311, doi: 10.1186\/s12936-015-1075-7 (2016).","journal-title":"Malaria J."},{"key":"BFsrep32762_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S1471-4922(02)02373-5","volume":"18","author":"NJ White","year":"2002","unstructured":"White, N. J. The assessment of antimalarial drug efficacy. Trends Parasitol. 18, 458\u2013464 (2002).","journal-title":"Trends Parasitol"},{"key":"BFsrep32762_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1128\/AAC.41.7.1413","volume":"41","author":"NJ White","year":"1997","unstructured":"White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41, 1413\u20131422 (1997).","journal-title":"Antimicrob. Agents Chemother"},{"key":"BFsrep32762_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/20427895","volume":"2","author":"R Ross","year":"1921","unstructured":"Ross, R. Observations On The Principle Of Repeated Medication For Curing Infections. The Brit. Med. J.l 2, 1\u20134, doi: 10.2307\/20427895 (1921).","journal-title":"The Brit. Med. J.l"},{"key":"BFsrep32762_CR38","doi-asserted-by":"publisher","first-page":"e1003151","DOI":"10.1371\/journal.pcbi.1003151","volume":"9","author":"K Kay","year":"2013","unstructured":"Kay, K. & Hastings, I. M. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLoS Comput Biol 9, e1003151, doi: 10.1371\/journal.pcbi.1003151 (2013).","journal-title":"PLoS Comput Biol"},{"key":"BFsrep32762_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10928-007-9069-x","volume":"34","author":"D Czock","year":"2007","unstructured":"Czock, D. & Keller, F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34, 727\u2013751 (2007).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"BFsrep32762_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1017\/S0031182098002480","volume":"116","author":"MB Hoshen","year":"1998","unstructured":"Hoshen, M. B., Stein, W. D. & Ginsburg, H. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 116, 407\u2013416 (1998).","journal-title":"Parasitology"},{"key":"BFsrep32762_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/jtbi.1997.0438","volume":"194","author":"DJ Austin","year":"1998","unstructured":"Austin, D. J., White, N. J. & Anderson, R. M. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194, 313\u2013339 (1998).","journal-title":"J. Theor. Biol."},{"key":"BFsrep32762_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1017\/S0031182099006368","volume":"121","author":"MB Hoshen","year":"2000","unstructured":"Hoshen, M. B., Heinrich, R., Stein, W. D. & Ginsburg, H. Mathematical modelling of the within-host dynamics of Plasmodium falciparum. Parasitology 121, 227\u2013235 (2000).","journal-title":"Parasitology"},{"key":"BFsrep32762_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S0031182099006332","volume":"121","author":"MB Hoshen","year":"2000","unstructured":"Hoshen, M. B., Na-Bangchang, K., Stein, W. D. & Ginsburg, H. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of \u2018dormancy\u2019, a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121, 237\u2013246 (2000).","journal-title":"Parasitology"},{"key":"BFsrep32762_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1017\/S0031182001008952","volume":"124","author":"MB Hoshen","year":"2002","unstructured":"Hoshen, M. B., Stein, W. D. & Ginsburg, H. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 124, 9\u201315 (2002).","journal-title":"Parasitology"},{"key":"BFsrep32762_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S003118200100854X","volume":"123","author":"MB Hoshen","year":"2001","unstructured":"Hoshen, M. B., Stein, W. D. & Ginsburg, H. D. Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine. Parasitology 123, 337\u2013346 (2001).","journal-title":"Parasitology"},{"key":"BFsrep32762_CR46","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1128\/AAC.44.12.3414-3424.2000","volume":"44","author":"JA Simpson","year":"2000","unstructured":"Simpson, J. A. et al. Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance. Antimicrob. Agents Chemother. 44, 3414\u20133424 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32762_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/1475-2875-11-303","volume":"11","author":"S Zaloumis","year":"2012","unstructured":"Zaloumis, S. et al. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria J.l 11, 303 (2012).","journal-title":"Malaria J.l"},{"key":"BFsrep32762_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1475-2875-13-62","volume":"13","author":"I Hastings","year":"2014","unstructured":"Hastings, I. & Hodel, E. M. Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? Malaria J. 13, 62 (2014).","journal-title":"Malaria J"},{"key":"BFsrep32762_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1475-2875-13-138","volume":"13","author":"E Hodel","year":"2014","unstructured":"Hodel, E., Kay, K., Hayes, D., Terlouw, D. & Hastings, I. Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malaria J. 13, 138 (2014).","journal-title":"Malaria J"},{"key":"BFsrep32762_CR50","doi-asserted-by":"crossref","unstructured":"Hodel, E. M., Kay, K. & Hastings, I. M. Incorporating stage specificity into pharmacological modelling of antimalarial drug treatment. Antimicrob. Agents Chemother. in press, doi: 10.1128\/AAC.01172-15 (2016).","DOI":"10.1128\/AAC.01172-15"},{"key":"BFsrep32762_CR51","doi-asserted-by":"crossref","unstructured":"Kay, K., Hodel, E. M. & Hastings, I. M. Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials. Antimicrob. Agents Chemother. 58, doi: 10.1128\/aac.02777-14 (2014).","DOI":"10.1128\/AAC.02777-14"},{"key":"BFsrep32762_CR52","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1128\/AAC.01712-10","volume":"55","author":"K Winter","year":"2011","unstructured":"Winter, K. & Hastings, I. M. Development, evaluation and application of an in silico model for antimalarial drug treatment and failure. Antimicrob. Agents Chemother. 55, 3380\u20133392 (2011).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32762","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:51:35Z","timestamp":1672876295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep32762"],"URL":"https:\/\/doi.org\/10.1038\/srep32762","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]},"assertion":[{"value":"27 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32762"}}